• 1
    Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998; 279: 10524.
  • 2
    Nakamura A, Yuasa T, Ujike A, Ono M, Nukiwa T, Ravetch JV, et al. Fcγ receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J Exp Med 2000; 191: 899906.
  • 3
    Song H, He C, Knaak C, Guthridge JM, Holers VM, Tomlinson S. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest 2003; 111: 187585.
  • 4
    Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 2005; 35: 2496506.
  • 5
    Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 52130.
  • 6
    Honda S, Nemoto K, Mae T, Kinjoh K, Kyogoku M, Kawamura H, et al. Mice with early onset of death (EOD) due to lupus glomerulonephritis. Clin Exp Immunol 1999; 116: 15363.
  • 7
    Ito MR, Ono M, Itoh J, Nose M. Bone marrow cell transfer of autoimmune diseases in a MRL strain of mice with a deficit in functional Fas ligand: dissociation of arteritis from glomerulonephritis. Pathol Int 2003; 53: 51824.
  • 8
    Ujike A, Ishikawa Y, Ono M, Yuasa T, Yoshino T, Fukumoto M, et al. Modulation of immunoglobulin (Ig) E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. J Exp Med 1999; 189: 15739.
  • 9
    Novak EK, Sweet HO, Prochazka M, Parentis M, Soble R, Reddington M, et al. Cocoa: a new mouse model for platelet storage pool deficiency. Br J Haematol 1988; 69: 3718.
  • 10
    Ciciotte SL, Gwynn B, Moriyama K, Huizing M, Gahl WA, Bonifacino JS, et al. Cappuccino, a mouse model of Hermansky-Pudlak syndrome, encodes a novel protein that is part of the pallidin-muted complex (BLOC-1). Blood 2003; 101: 44027.
  • 11
    McNicol A, Israels SJ. Platelet dense granules: structure, function and implications for haemostasis. Thromb Res 1999; 95: 118.
  • 12
    Gwynn B, Ciciotte SL, Hunter SJ, Washburn LL, Smith RS, Andersen SG, et al. Defects in the cappuccino (cno) gene on mouse chromosome 5 and human 4p cause Hermansky-Pudlak syndrome by an AP-3-independent mechanism. Blood 2000; 96: 422735.
  • 13
    Quismorio FP Jr. Hematologic and lymphoid abnormalities in systemic lupus erythematosus. In: WallaceDJ, HahnBH, QuismorioFPJr, KlinenbergJR, editors. Dubois' lupus erythematosus. 5th ed. Baltimore: Williams & Wilkins; 1997. p. 103751.
  • 14
    Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 2005; 64: 13669.
  • 15
    Cameron JS. Glomerulonephritis: current problems and understanding. J Lab Clin Med 1982; 99: 75587.
  • 16
    Horn A, Avenarius HJ, Deicher H. Thrombocyte function and thrombocyte-associated immunoglobulins in patients with systemic lupus erythematosus and chronic polyarthritis. Klin Wochenschr 1990; 68: 4605. In German.
  • 17
    Frampton G, Hildreth G, Hartley B, Cameron JS, Heldin CH, Wasteson A. Could platelet-derived growth factor have a role in the pathogenesis of lupus nephritis? [letter]. Lancet 1988; 332: 343.
  • 18
    Clark WF, Linton AL, Cordy PE, Keown PE, Lohmann RC, Lindsay RM. Immunologic findings, thrombocytopenia and disease activity in lupus nephritis. Can Med Assoc J 1978; 118: 13915.
  • 19
    Clark WF, Lewis ML, Cameron JS, Parsons V. Intrarenal platelet consumption in the diffuse proliferative nephritis of systemic lupus erythematosus. Clin Sci Mol Med 1975; 49: 24752.
  • 20
    Heeringa P, van Goor H, Moshage H, Klok PA, Huitema MG, de Jager A, et al. Expression of iNOS, eNOS, and peroxynitrite-modified proteins in experimental anti-myeloperoxidase associated crescentic glomerulonephritis. Kidney Int 1998; 53: 38293.
  • 21
    Nagao T, Nagamatsu T, Suzuki Y. Effect of DP-1904, a thromboxane A2 synthase inhibitor, administered from the autologous phase on crescentic-type anti-GBM nephritis in rats. Jpn J Pharmacol 1995; 68: 13744.
  • 22
    Le Hir M, Haas C, Marino M, Ryffel B. Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. Lab Invest 1998; 78: 162531.
  • 23
    Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD. Antibody blockade of TNF-α reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 2005; 67: 181220.
  • 24
    Lan HY, Nikolic-Paterson DJ, Mu W, Vannice JL, Atkins RC. Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Kidney Int 1995; 47: 13039.
  • 25
    Timoshanko JR, Kitching AR, Iwakura Y, Holdsworth SR, Tipping PG. Contributions of IL-1β and IL-1α to crescentic glomerulonephritis in mice. J Am Soc Nephrol 2004; 15: 9108.
  • 26
    Zhou A, Ueno H, Shimomura M, Tanaka R, Shirakawa T, Nakamura H, et al. Blockade of TGF-β action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. Kidney Int 2003; 64: 92101.
  • 27
    Sadanaga A, Nakashima H, Masutani K, Miyake K, Shimizu S, Igawa T, et al. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum 2005; 52: 398796.
  • 28
    Yang N, Nikolic-Paterson DJ, Ng YY, Mu W, Metz C, Bacher M, et al. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. Mol Med 1998; 4: 41324.
  • 29
    Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, et al. A new anti-inflammatory compound, FR167653, ameliorates crescentic glomerulonephritis in Wistar-Kyoto rats. J Am Soc Nephrol 2000; 11: 153441.
  • 30
    Hasegawa H, Kohno M, Sasaki M, Inoue A, Ito MR, Terada M, et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003; 48: 255566.
  • 31
    Inoue A, Hasegawa H, Kohno M, Ito MR, Terada M, Imai T, et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 2005; 52: 152233.
  • 32
    Lelongt B, Ronco P. Role of matrix metalloproteinases in kidney development and glomerulopathy: lessons from transgenic mice. Nephrol Dial Transplant 2002; 17: 2831.
  • 33
    Kaneko Y, Sakatsume M, Xie Y, Kuroda T, Igashima M, Narita I, et al. Macrophage metalloelastase as a major factor for glomerular injury in anti-glomerular basement membrane nephritis. J Immunol 2003; 170: 337785.
  • 34
    Yanagita M, Ishimoto Y, Arai H, Nagai K, Ito T, Nakano T, et al. Essential role of Gas6 for glomerular injury in nephrotoxic nephritis. J Clin Invest 2002; 110: 23946.
  • 35
    Drew AF, Tucker HL, Liu H, Witte DP, Degen JL, Tipping PG. Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice. Am J Physiol Renal Physiol 2001; 281: 115763.
  • 36
    Kitching AR, Tipping PG, Mutch DA, Huang XR, Holdsworth SR. Interleukin-4 deficiency enhances Th1 responses and crescentic glomerulonephritis in mice. Kidney Int 1998; 53: 1128.
  • 37
    Kitching AR, Holdsworth SR, Tipping PG. IFN-γ mediates crescent formation and cell-mediated immune injury in murine glomerulonephritis. J Am Soc Nephrol 1999; 10: 7529.
  • 38
    Kitching AR, Tipping PG, Holdsworth SR. IL-12 directs severe renal injury, crescent formation and Th1 responses in murine glomerulonephritis. Eur J Immunol 1999; 29: 110.
  • 39
    Kanai H, Hiromura K, Kuroiwa T, Maezawa A, Yano S, Naruse T. Role of serotonin in nephrotoxic serum nephritis in WKY rats. J Lab Clin Med 1997; 129: 55766.
  • 40
    Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets 2001; 12: 26173.
  • 41
    Angelillo-Scherrer A, de Frutos PG, Aparicio C, Melis E, Savi P, Lupu F, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001; 7: 21521.
  • 42
    Meyerhoff J, Dorsch CA. Decreased platelet serotonin levels in systemic lupus erythematosus. Arthritis Rheum 1981; 24: 1495500.
  • 43
    Parbtani A, Frampton G, Cameron JS. Platelet and plasma serotonin concentrations in glomerulonephritis, II. Clin Nephrol 1980; 14: 11223.
  • 44
    Parbtani A, Frampton G, Yewdall V, Kasai N, Cameron JS. Platelet and plasma serotonin in glomerulonephritis, III: the nephritis of systemic lupus erythematosus. Clin Nephrol 1980; 14: 16472.
  • 45
    Igarashi Y. Sarpogrelate, a serotonin receptor (5-HT2A) antagonist, ameliorates renal damage in experimental mesangial proliferative glomerulonephritis. Clin Exp Nephrol 2000; 4: 193200.
  • 46
    Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 2004; 104: 5981.
  • 47
    Falcon-Perez JM, Starcevic M, Gautam R, Dell'Angelica EC. BLOC-1, a novel complex containing the pallidin and muted proteins involved in the biogenesis of melanosomes and platelet-dense granules. J Biol Chem 2002; 277: 281919.
  • 48
    Li W, Zhang Q, Oiso N, Novak EK, Gautam R, O'Brien EP, et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet 2003; 35: 849.
  • 49
    Gwynn B, Martina JA, Bonifacino JS, Sviderskaya EV, Lamoreux ML, Bennett DC, et al. Reduced pigmentation (rp), a mouse model of Hermansky-Pudlak syndrome, encodes a novel component of the BLOC-1 complex. Blood 2004; 104: 31819.
  • 50
    Starcevic M, Dell'Angelica EC. Identification of snapin and three novel proteins (BLOS1, BLOS2, and BLOS3/reduced pigmentation) as subunits of biogenesis of lysosome-related organelles complex-1 (BLOC-1). J Biol Chem 2004; 279: 28393401.